Acorda Therapeutics Inc (NASDAQ:ACOR) insider Andrew A. Hindman sold 753 shares of the firm’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $20.56, for a total value of $15,481.68. Following the completion of the sale, the insider now owns 5,171 shares of the company’s stock, valued at $106,315.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ:ACOR opened at $18.63 on Friday. Acorda Therapeutics Inc has a twelve month low of $15.60 and a twelve month high of $36.35. The firm has a market cap of $894.57 million, a PE ratio of 11.33 and a beta of 1.45. The company has a quick ratio of 3.95, a current ratio of 4.03 and a debt-to-equity ratio of 0.57.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Wednesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.15. Acorda Therapeutics had a positive return on equity of 13.72% and a negative net margin of 24.88%. The business had revenue of $142.80 million during the quarter, compared to the consensus estimate of $82.74 million. During the same period last year, the company earned $0.43 earnings per share. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Acorda Therapeutics Inc will post 0.08 earnings per share for the current year.

A number of brokerages recently issued reports on ACOR. ValuEngine downgraded Acorda Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Oppenheimer set a $21.00 price target on Acorda Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, September 12th. Cantor Fitzgerald began coverage on Acorda Therapeutics in a research report on Thursday, August 23rd. They issued a “neutral” rating and a $32.00 price target for the company. HC Wainwright set a $31.00 price target on Acorda Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 11th. Finally, BidaskClub downgraded Acorda Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 17th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Acorda Therapeutics currently has an average rating of “Hold” and a consensus target price of $26.56.

Several large investors have recently added to or reduced their stakes in ACOR. Principal Financial Group Inc. lifted its position in shares of Acorda Therapeutics by 2.9% during the first quarter. Principal Financial Group Inc. now owns 367,973 shares of the biopharmaceutical company’s stock worth $8,703,000 after purchasing an additional 10,536 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Acorda Therapeutics by 15.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 57,010 shares of the biopharmaceutical company’s stock worth $1,637,000 after purchasing an additional 7,811 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Acorda Therapeutics during the second quarter worth $229,000. First Trust Advisors LP bought a new stake in shares of Acorda Therapeutics during the second quarter worth $2,801,000. Finally, Alps Advisors Inc. lifted its position in shares of Acorda Therapeutics by 8.5% during the second quarter. Alps Advisors Inc. now owns 68,306 shares of the biopharmaceutical company’s stock worth $1,960,000 after purchasing an additional 5,333 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “Andrew A. Hindman Sells 753 Shares of Acorda Therapeutics Inc (ACOR) Stock” was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2018/12/08/andrew-a-hindman-sells-753-shares-of-acorda-therapeutics-inc-acor-stock.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Story: How is the S&P 500 index different from the DJIA?

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.